BioTime, Inc.
(NYSE Amex Equities : BTX)

( )
BTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
MDTMedtronic PLC
2.51%91.000.6%$444.99m
TMOThermo Fisher Scientific Inc.
2.38%271.671.0%$433.69m
ISRGIntuitive Surgical, Inc.
0.37%485.372.4%$388.14m
BDXBecton, Dickinson and Company
-0.02%235.681.1%$376.74m
ABTAbbott Laboratories
-0.01%76.260.8%$367.37m
ALGNAlign Technology, Inc.
-0.27%318.826.3%$341.92m
BSXBoston Scientific Corporation
0.11%37.741.1%$309.81m
ABMDABIOMED, Inc.
-1.31%262.003.3%$258.27m
SYKStryker Corporation
0.02%185.951.3%$211.09m
BAXBaxter International Inc.
0.37%75.581.7%$197.08m
EWEdwards Lifesciences Corporation
0.38%172.651.2%$193.00m
WATWaters Corporation
0.50%207.183.8%$157.08m
ZBHZimmer Biomet Holdings, Inc.
-0.83%115.151.7%$144.43m
DXCMDexCom, Inc.
0.14%118.758.3%$130.28m
IDXXIDEXX Laboratories, Inc.
0.42%250.383.7%$124.02m

Company Profile

BioTime, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.